Zioptan is an eye pressure reducing drug owned by Akorn. The active ingredient in Zioptan is tafluprost, which makes it effective against ocular hypertension or open-angle glaucoma. The drug was first authorized for market use on February 10, 2012.
Zioptan has a total of 3 drug patents, out of which one patent has already expired. The remaining patents, US10864159 and US9999593, both titled 'Method and composition for treating ocular hypertension and glaucoma' are set to expire on May 28, 2029. After the expiration, generics of Zioptan will likely become available.
Zioptan is used for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. The active ingredient in Zioptan, tafluprost, helps alleviate symptoms by lowering the eye pressure.
The patents of Zioptan are set to fully expire on May 28, 2029. This will also mark the potential availability date of Zioptan generic. Patents US10864159 and US9999593, focusing on the 'Method and composition for treating ocular hypertension and glaucoma' are valid until this date. An earlier patent US5886035 titled 'Difluoroprostaglandin derivatives and their use' has already expired on December 18, 2022. Below are the details of the patent: